A novel endogenous erythropoietin mediated pathway prevents axonal degeneration

Annals of Neurology

Volumn 56, Issue 6, 2004, Pages 815-826

  Keswani, Sanjay C ^a,d   Buldanlioglu, Ulas ^a   Fischer, Angela ^a   Reed, Nicole ^a   Polley, Michelle ^a   Liang, Hong ^a   Zhou, Chunhua ^a   Jack, Christelene ^a   Leitz, Gerhard J ^c   Hoke, Ahmet ^a,b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b Department of Neuroscience ^*  (United States)

^c Ortho McNeil Pharmaceutical Incorporated   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; NITRIC OXIDE; RECOMBINANT ERYTHROPOIETIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; GLIA CELL; HORMONE RELEASE; HUMAN IMMUNODEFICIENCY VIRUS; IN VITRO STUDY; IN VIVO STUDY; MALE; MUSCLE WEAKNESS; NERVE CELL NECROSIS; NERVE FIBER DEGENERATION; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NEUROPATHY; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RAT; SCHWANN CELL; SENSORY NEUROPATHY; SIGNAL TRANSDUCTION;

ANIMALS; AXONS; CELLS, CULTURED; ERYTHROPOIETIN; NERVE DEGENERATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ERYTHROPOIETIN; SCHWANN CELLS; SIGNAL TRANSDUCTION;

EID: 9644299706     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20285     Document Type: Article

References (45)

1. Sidenius P. The axonopathy of diabetic neuropathy. Diabetes 1982;31:356-363.
2. Pardo CA, McArthur JC, Griffin JW. HIV neuropathy: insights in the pathology of HIV peripheral nerve disease. J Peripher Nerv Syst 2001;6:21-27.
3. Raff MC, Whitmore AV, Finn JT. Axonal self-destruction and neurodegeneration. Science 2002;296:868-871.
4. Zhai Q, Wang J, Kim A, et al. Involvement of the ubiquitin-proteasome system in the early stages of wallerian degeneration. Neuron 2003;39:217-225.
5. Ehlers MD. Deconstructing the axon: Wallerian degeneration and the ubiquitin-proteasome system. Trends Neurosci 2004;27:3-6.
6. Glass JD, Culver DG, Levey AI, Nash NR. Very early activation of m-calpain in peripheral nerve during Wallerian degeneration. J Neurol Sci 2002;196:9-20.
7. Korhonen L, Lindholm D. The ubiquitin proteasome system in synaptic and axonal degeneration: a new twist to an old cycle. J Cell Biol 2004;165:27-30.
8. Coleman MP, Perry VH. Axon pathology in neurological disease: a neglected therapeutic target. Trends Neurosci 2002;25:532-537.
9. Ruscher K, Freyer D, Karsch M, et al. Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J Neurosci 2002;22:10291-10301.
10. Brockes JP, Fields KL, Raff MC. Studies on cultured rat Schwann cells. I. Establishment of purified populations from cultures of peripheral nerve. Brain Res 1979;165:105-118.
11. Eldridge CF, Bunge MB, Bunge RP, Wood PM. Differentiation of axon-related Schwann cells in vitro. I. Ascorbic acid regulates basal lamina assembly and myelin formation. J Cell Biol 1987;105:1023-1034.
12. Kojima H, Nakatsubo N, Kikuchi K, et al. Detection and imaging of nitric oxide with novel fluorescent indicators: diaminofluoresceins. Anal Chem 1998;70:2446-2453.
13. Ko MH, Chen WP, Lin-Shiau SY, Hsieh ST. Age-dependent acrylamide neurotoxicity in mice: morphology, physiology, and function. Exp Neurol 1999;158:37-46.
14. Fullerton PM, Barnes JM. Peripheral neuropathy in rats produced by acrylamide. Br J Ind Med 1966;23:210-221.
15. Crofton KM, Padilla S, Tilson HA, et al. The impact of dose rate on the neurotoxicity of acrylamide: the interaction of administered dose, target tissue concentrations, tissue damage, and functional effects. Toxicol Appl Pharmacol 1996;139:163-176.
16. Dixon WJ. Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 1980;20:441-462.
17. Ma J, Smith BP, Smith TL, et al. Juvenile and adult rat neuromuscular junctions: density, distribution, and morphology. Muscle Nerve 2002;26:804-809.
18. Keswani SC, Chander B, Hasan C, et al. FK506 is neuroprotective in a model of antiretroviral toxic neuropathy. Ann Neurol 2003;53:57-64.
19. Keswani SC, Polley M, Pardo CA, et al. Chemokine receptors on Schwann cells mediate HIV-1 gp120 neurotoxicity in primary sensory neurons. Ann Neurol 2003;54:287-296.
20. LoPachin RM Jr, Lehning EJ. Acrylamide-induced distal axon degeneration: a proposed mechanism of action. Neurotoxicology 1994;15:247-259.
21. DeGrandchamp RL, Lowndes HE. Early degeneration and sprouting at the rat neuromuscular junction following acrylamide administration. Neuropathol Appl Neurobiol 1990;16:239-254.
22. Gold BG, Griffin JW, Price DL. Slow axonal transport in acrylamide neuropathy: different abnormalities produced by single-dose and continuous administration. J Neurosci 1985;5:1755-1768.
23. LoPachin RM. Redefining toxic distal axonopathies. Toxicol Lett 2000;112-113:23-33.
24. Keswani SC, Pardo CA, Cherry CL, et al. HIV-associated sensory neuropathies. AIDS 2002;16:2105-2117.
25. Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol 2001;14:271-278.
26. Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 2003;206:165-171.
27. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 2001;412:641-647.
28. Siren AL, Fratelli M, Brines M, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Nad Acad Sci USA 2001;98:4044-4049.
29. Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 2002;106:2973-2979.
30. Gorio A, Gokmen N, Erbayraktar S, et al. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci USA 2002;99:9450-9455.
31. Campana WM, Myers RR. Exogenous erythropoietin protects against dorsal root ganglion apoptosis and pain following peripheral nerve injury. Eur J Neurosci 2003;18:1497-1506
32. Baciu I, Oprisiu C, Derevenco P, et al. The brain and other sites of erythropoietin production. Rom J Physiol 2000;37:3-14
33. Campana WM, Myers RR. Erythropoietin and erythropoietin receptors in the peripheral nervous system: changes after nerve injury. FASEB J 2001;15:1804-1806
34. Dame C, Bartmann P, Wolber E, et al. Erythropoietin gene expression in different areas of the developing human central nervous system. Brain Res Dev Brain Res 2000;125:69-74.
35. Dame C, Juul SE, Christensen RD. The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential. Biol Neonate 2001;79:228-235.
36. Juul SE, Anderson DK, Li Y, Christensen RD. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res 1998;43:40-49.
37. Juul SE, Yachnis AT, Rojiani AM, Christensen RD. Immunohistochemical localization of erythropoietin and its receptor in the developing human brain. Pediatr Dev Pathol 1999;2:148-158.
38. Li Y, Juul SE, Morris-Wiman JA, et al. Erythropoietin receptors are expressed in the central nervous system of mid-trimester human fetuses. Pediatr Res 1996;40:376-380.
39. Masuda S, Nagao M, Takahata K, et al. Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem 1993;268:11208-11216.
40. Mizusawa I, Abe S, Kanno K, et al. Expression of cytokines, neurotrophins, neurotrophin receptors and NOS mRNA in dorsal root ganglion of a rat tourniquet model. Leg Med (Tokyo) 2003;5:S271-S274.
41. Haga KK, Gregory LJ, Hicks CA, et al. The neuronal nitric oxide synthase inhibitor, TRIM, as a neuroprotective agent: effects in models of cerebral ischaemia using histological and magnetic resonance imaging techniques. Brain Res 2003;993:42-53.
42. Bolanos JP, Garcia-Nogales P, Almeida A. Provoking neuroprotection by peroxynitrite. Curr Pharm Des 2004;10:867-877.
43. Wiggins AK, Shen PJ, Gundlach AL. Neuronal-NOS adaptor protein expression after spreading depression: implications for NO production and ischemic tolerance. J Neurochem 2003;87:1368-1380.
44. Keilhoff G, Fansa H, Wolf G. Differences in peripheral nerve degeneration/regeneration between wild-type and neuronal nitric oxide synthase knockout mice. J Neurosci Res 2002;68:432-441.
45. Goldman SA, Nedergaard M. Erythropoietin strikes a new cord. Nat Med 2002;8:785-787.